Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.48 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: teprasiran, siremadlin, idasanutlin +6 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 69 Parkinson's papers of 31,617 | 0.44 |
| pathways Reactome | 47 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 0269
Sealed predictions
- TP53 in dopamine neurons, braak-0.38 (p 0.311) → +0.11 (p 0.777)receipt 0274
Swarm cases
receipt 0274: TP53 in dopamine neurons, braak
- power
- full sample -0.16 (p 0.521, n 18), 95% CI -0.58 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.398, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.603, n 18). could be the mix.
- skeptic
- leave-one-out range -0.31 to -0.05, sign flips 0; without severely affected donors -0.16 (p 0.521, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TP53 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts